Innovasis Signs Private-Label Agreement with Stability Biologics

By Julie A. Vetalice

Innovasis expanded their orthobiologics footprint, signing a private-label agreement with Stability Biologics, an FDA-registered tissue processing and distribution center that includes Physio® bone allograft. The private-labeled products are slated for launch by year-end.

Innovasive supplies spinal hardware and allograft tissue such as DBM and synthetic bone graft substitutes to physicians, hospitals and ambulatory surgery centers around the world, while Stability Biologics human allograft tissue for distribution and use in spine, orthopaedics and wound care.

Source: Innovasis, Inc.

Product Labels: Bone Graft Materials/DBM, Synthetic Bone Graft

Tags: M&A